ERAS-013
Advanced solid tumors with RAS/MAPK pathway alterations
PreclinicalActive
Key Facts
Indication
Advanced solid tumors with RAS/MAPK pathway alterations
Phase
Preclinical
Status
Active
Company
About Erasca
Erasca is a clinical-stage biotech singularly focused on developing therapies to 'erase' cancers driven by the RAS/MAPK pathway, which affects ~5.5 million new patients annually. The company's core strategy is built on its MAPKlamp™ platform, designed to overcome resistance by simultaneously targeting multiple nodes within the pathway. With a deep pipeline of small molecules, degraders, and bispecific antibodies, and led by a founder with a proven track record in precision oncology, Erasca aims to achieve durable pathway suppression and deliver transformative combination regimens.
View full company profile